论文部分内容阅读
目的探究瑞舒伐他汀对急性脑梗死患者血清VS-2(血管抑制因子)、sⅠ-CAM-1(可溶性细胞黏附因子)及MMp2(基质金属蛋白酶)的影响。方法选择2014年9月—2016年7月收治的急性脑梗死(ACI)患者112例为研究对象,使用随机数表法分为两组,各56例。给予对照组患者急性脑梗死常规治疗,观察组在此基础上加用瑞舒伐他汀,对比两组患者治疗前后血清VS-2、sⅠ-CAM-1、MMp2水平及不良反应发生情况。结果治疗前两组血清VS-2、sⅠ-CAM-1、MMp2水平对比,差异不显著(P>0.05);治疗后两组上述指标均较治疗前有所下降,观察组优于对照组,差异有统计学意义(P<0.05);两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论瑞舒伐他汀可有效降低急性脑梗死患者血清VS-2、sⅠ-CAM-1、MMp2水平,兼具较高安全性。
Objective To investigate the effect of rosuvastatin on serum levels of VS-2, sⅠ-CAM-1 (soluble cell adhesion molecule) and MMp2 (matrix metalloproteinases) in patients with acute cerebral infarction. Methods A total of 112 acute cerebral infarction (ACI) patients from September 2014 to July 2016 were enrolled in this study. They were divided into two groups (n = 56) using random number table. The patients in the control group were given conventional treatment of acute cerebral infarction. The observation group was given rosuvastatin on this basis. The levels of VS-2, sⅠ-CAM-1, MMp2 and adverse reactions in the two groups were compared before and after treatment. Results There was no significant difference in serum levels of VS-2, sⅠ-CAM-1 and MMp2 between the two groups before treatment (P> 0.05). After treatment, the above indexes in both groups were lower than those before treatment, The difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusions Rosuvastatin can effectively reduce the serum levels of VS-2, sⅠ-CAM-1 and MMp2 in patients with acute cerebral infarction, with high safety.